LGALS3 and heart failure: Large-scale population studies, such as the Framingham Heart Study and PREVEND, have established galectin-3 (gal-3) as a biomarker associated with an elevated risk of heart failure (HF), cardiovascular mortality, and all-cause mortality [2,3].